ALPHARETTA, Ga., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...
A study using AAO's IRIS Registry demonstrates Eylea HD 8 mg improves vision in treatment-naive patients with wet age-related macular degeneration or diabetic macular edema with previously treated ...
In a real-life setting, an observe-and-plan regimen for anti-VEGF injections in neovascular age-related macular degeneration ...
DAVIO-2 for wet AMD and VERONA for DME. In the DAVIO-2 trial, patients previously treated with approximately 10 injections in ...
4D-150 demonstrated robust and durable clinical activity across all wet age-related macular degeneration (wet AMD) patient populations based on longest available follow-up data In broad population ...
EyePoint faces clinical, commercial hurdles despite DME, AMD progress and solid funding through 2027. Read why EYPT stock is ...
Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and improve vision outcomes for patients with wet AMD ARTEMIS ...
3E10 vg/eye achieved an 83% reduction in injection burden vs. projected on-label aflibercept 2 mg Q8W, 70% required 0-1 supplemental injection, and 57% were injection-free through 52 weeks In the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback